---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123340"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:43:37.226363+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nkarta Q3 net loss $28.3M; cash $405.3M; drops NHL, focuses NKX019 on autoimmune

## Summary
- Net loss of $28.3M ($0.39 per basic/diluted share) for Q3 2024; cash, equivalents, investments $405.3M.
- First patient dosed in Ntrust-1 (lupus nephritis) and CUIMC IST (SLE); enrollment ongoing.
- Ntrust-2 (systemic sclerosis, myositis, vasculitis) enrollment expected by year-end 2024; preliminary data in 2025.
- Forgoes further NKX019 development in non-Hodgkin lymphoma; no new NHL trials planned.
- Current cash expected to fund operations into late 2027.

## SEC filing metadata
- accession: 0000950170-24-123340
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017024123340/0000950170-24-123340-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017024123340/nktx-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123340
- JSON: https://secwatch.observer/filing/0000950170-24-123340.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123340.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.